NSCs have been demonstrated to be very useful in grafts into the mammalian central nervous system to investigate the exploitation of NSC for the therapy of neurodegenerative disorders in animal models of neurodegenerative diseases. To push cell therapy in CNS on stage of clinical application, it is necessary to establish a continuous and standardized, clinical grade (i.e., produced following the good manufacturing practice guidelines) human neural stem cell lines. In this chapter we will illustrate some of the protocols for the production and characterization routinely used into our GMP “cell factory” for the production of “clinical grade” human neural stem cell lines already in use in clinical trials on neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS— Clinicaltrials.gov number NCT01640067) and secondary progressive multiple sclerosis (SPMS— Clinicaltrials.gov number NCT03282760).

Gelati, M., Profico, D., Ferrari, D., Vescovi, A. (2022). Culturing and Expansion of “Clinical Grade” Neural Stem Cells from the Fetal Human Central Nervous System. In L.C. Deleyrolle (a cura di), Neural Progenitor Cells - Methods and Protocols (pp. 57-66). Humana Press Inc. [10.1007/978-1-0716-1783-0_5].

Culturing and Expansion of “Clinical Grade” Neural Stem Cells from the Fetal Human Central Nervous System

Vescovi A. L.
Ultimo
2022

Abstract

NSCs have been demonstrated to be very useful in grafts into the mammalian central nervous system to investigate the exploitation of NSC for the therapy of neurodegenerative disorders in animal models of neurodegenerative diseases. To push cell therapy in CNS on stage of clinical application, it is necessary to establish a continuous and standardized, clinical grade (i.e., produced following the good manufacturing practice guidelines) human neural stem cell lines. In this chapter we will illustrate some of the protocols for the production and characterization routinely used into our GMP “cell factory” for the production of “clinical grade” human neural stem cell lines already in use in clinical trials on neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS— Clinicaltrials.gov number NCT01640067) and secondary progressive multiple sclerosis (SPMS— Clinicaltrials.gov number NCT03282760).
Capitolo o saggio
Clinical grade; Human central nervous system; Neural stem cells; Precursor cells; Therapy;
English
Neural Progenitor Cells - Methods and Protocols
9781071617823
Gelati, M., Profico, D., Ferrari, D., Vescovi, A. (2022). Culturing and Expansion of “Clinical Grade” Neural Stem Cells from the Fetal Human Central Nervous System. In L.C. Deleyrolle (a cura di), Neural Progenitor Cells - Methods and Protocols (pp. 57-66). Humana Press Inc. [10.1007/978-1-0716-1783-0_5].
Gelati, M; Profico, D; Ferrari, D; Vescovi, A
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/397818
Citazioni
  • Scopus 1
  • ???jsp.display-item.citation.isi??? ND
Social impact